The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
03
12
2018
accepted:
20
02
2019
revised:
25
01
2019
pubmed:
6
3
2019
medline:
22
6
2021
entrez:
6
3
2019
Statut:
ppublish
Résumé
The number of HLA-haploidentical hematopoietic cell transplants continues to increase worldwide due to recent improvements in outcomes, allowing more patients with hematological malignancies and non-malignant disorders to benefit from this procedure and have a chance to cure their disease. Despite these encouraging results, questions remain as multiple donors are usually available for transplantation, and choosing the best HLA-haploidentical donor for transplantation remains a challenge. Several approaches to haploidentical transplantation have been developed over time and, based on the graft received, can be grouped as follows: T-cell depleted haploidentical transplants, either complete or partial, or with T-cell replete grafts, performed with post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, or G-CSF-primed bone marrow graft and enhanced GVHD prophylaxis. Carefully selecting the donor can help optimize transplant outcomes for recipients of haploidentical donor transplants. Variables usually considered in the donor selection include presence of donor-specific antibodies in the recipient, donor age, donor/recipient gender and ABO combinations, and immunogenic variables, such as natural killer cell alloreactivity or KIR haplotype. Here we provide a comprehensive review of available evidence for selecting haploidentical donors for transplantation, and summarize the recommendations from the European Society for Blood and Marrow Transplantation (EBMT) on donor selection for different transplant platforms.
Identifiants
pubmed: 30833742
doi: 10.1038/s41409-019-0499-z
pii: 10.1038/s41409-019-0499-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
12-24Références
Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51:778–85.
pubmed: 26901703
pmcid: 4889523
doi: 10.1038/bmt.2016.18
Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52:811–7.
pubmed: 28287639
pmcid: 5467246
doi: 10.1038/bmt.2017.34
Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–54.
pubmed: 15753458
doi: 10.1200/JCO.2005.09.117
Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124:638–44.
pubmed: 24923299
doi: 10.1182/blood-2014-03-564401
Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion. Blood. 2017;130:677–85.
pubmed: 28588018
doi: 10.1182/blood-2017-04-779769
Roy D-C, Lachance S, Roy J, Walker I, Maertens J, Delisle J-S, et al. Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL. Blood. 2016;128:1226.
doi: 10.1182/blood.V128.22.1226.1226
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.
pubmed: 18489989
pmcid: 2633246
doi: 10.1016/j.bbmt.2008.03.005
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291–7.
doi: 10.1038/sj.bmt.1705445
pubmed: 16883312
Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117–22.
pubmed: 22940057
doi: 10.1016/j.bbmt.2012.08.014
Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplant. 2015;50(Suppl 2):S37–9.
pubmed: 26039205
doi: 10.1038/bmt.2015.93
Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–6.
pubmed: 23423745
doi: 10.1200/JCO.2012.44.3523
Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–40.
pubmed: 26130705
pmcid: 4543223
doi: 10.1182/blood-2015-04-639831
Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016;34:3141–9.
pubmed: 27269951
pmcid: 5012706
doi: 10.1200/JCO.2015.66.3476
Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, et al. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv. 2018;2:1180–6.
pubmed: 29794073
pmcid: 5998932
doi: 10.1182/bloodadvances.2018018291
Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956–62.
pubmed: 25940714
doi: 10.1182/blood-2015-02-627786
Wang Y, Wang HX, Lai YR, Sun ZM, Wu DP, Jiang M, et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia. 2016;30:2055–63.
pubmed: 27133816
doi: 10.1038/leu.2016.110
Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. Clin Cancer Res. 2016;22:3467–76.
pubmed: 26927664
doi: 10.1158/1078-0432.CCR-15-2335
Lorentino F, Labopin M, Bernardi M, Ciceri F, Socie G, Cornelissen JJ, et al. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018;93:1236–44.
pubmed: 30058714
doi: 10.1002/ajh.25231
Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11:55.
pubmed: 29661208
pmcid: 5902953
doi: 10.1186/s13045-018-0598-0
Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand? Hematol Am Soc Hematol Educ Program. 2012;2012:230–6.
doi: 10.1182/asheducation.V2012.1.230.3798312
Bastien JP, Krosl G, Therien C, Rashkovan M, Scotto C, Cohen S, et al. Photodepletion differentially affects CD4 + Tregs versus CD4 + effector T cells from patients with chronic graft-versus-host disease. Blood. 2010;116:4859–69.
pubmed: 20798236
doi: 10.1182/blood-2010-03-273193
Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta + T and B cells in children with nonmalignant disorders. Blood. 2014;124:822–6.
pubmed: 24869942
doi: 10.1182/blood-2014-03-563817
Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112:3574–81.
pubmed: 18606875
doi: 10.1182/blood-2008-02-140095
Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18:1859–66.
pubmed: 22863841
doi: 10.1016/j.bbmt.2012.06.019
Kongtim P, Pingali SR, Jimenez AM, Rondon G, Chen J, Oran B, et al. Haploidentical transplantation (HaploSCT) with post-transplant cyclophosphamide (PTCy) and melphalan-based conditioning: a retrospective analysis of the first 100 patients treated at MD Anderson Cancer Center. ASCO Meet Abstr. 2014;32(15_suppl):7017.
Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134.
pubmed: 28676064
pmcid: 5496245
doi: 10.1186/s13045-017-0502-3
Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124:843–50.
pubmed: 24916508
doi: 10.1182/blood-2014-03-563130
Al Malki MM, Horowitz M, Handgretinger R, Leung W, Roy DC, Huang XJ, et al. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016;22:594–604.
pubmed: 26806585
doi: 10.1016/j.bbmt.2016.01.001
pmcid: 7104805
O’Reilly RJ, Keever C, Kernan NA, Brochstein J, Collins N, Flomenberg N, et al. HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplant Proc. 1987;19(6 Suppl 7):55–60.
pubmed: 3321647
Ash RC, Horowitz MM, Gale RP, van Bekkum DW, Casper JT, Gordon-Smith EC, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 1991;7:443–52.
pubmed: 1873591
Ciurea SO, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J, et al. Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1169–75.
pubmed: 21126598
doi: 10.1016/j.bbmt.2010.11.020
Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010;45:429–36.
pubmed: 19668237
doi: 10.1038/bmt.2009.189
Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Eng J Med. 2011;365:1673–83.
doi: 10.1056/NEJMoa1106152
Bastien JP, Roy J, Roy DC. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Semin Oncol. 2012;39:674–82.
pubmed: 23206844
doi: 10.1053/j.seminoncol.2012.09.004
Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009;10:489–500.
pubmed: 19345145
doi: 10.1016/S1470-2045(09)70074-9
Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443–58.
pubmed: 22576252
pmcid: 3552454
doi: 10.1038/nri3212
Li Pira G, Malaspina D, Girolami E, Biagini S, Cicchetti E, Conflitti G, et al. Selective depletion of alphabeta T cells and B cells for human leukocyte antigen-haploidentical hematopoietic stem cell transplantation. A three-year follow-up of procedure efficiency. Biol Blood Marrow Transplant. 2016;22:2056–64.
pubmed: 27519279
doi: 10.1016/j.bbmt.2016.08.006
Bertaina A, Zecca M, Buldini B, Sacchi N, Algeri M, Saglio F, et al. Unrelated donor vs HLA-haploidentical alpha/beta T-cell and B-cell depleted HSCT in children with acute leukemia. Blood 2018;132:2594–607.
pubmed: 30348653
doi: 10.1182/blood-2018-07-861575
Berenbaum MC, Brown IN. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature. 1963;200:84.
pubmed: 14074645
doi: 10.1038/200084a0
Santos GW, Owens AH. Production of graft-versus-host disease in the rat and its treatment with cytotoxic agents. Nature. 1966;210:139–40.
pubmed: 5962069
doi: 10.1038/210139a0
Mayumi H, Good RA. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide. J Exp Med. 1989;169:213–38.
pubmed: 2642528
doi: 10.1084/jem.169.1.213
Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456–64.
pubmed: 11719388
doi: 10.1182/blood.V98.12.3456
O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.
pubmed: 12171484
doi: 10.1053/bbmt.2002.v8.pm12171484
Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolanos-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16:482–9.
pubmed: 19925877
pmcid: 2998606
doi: 10.1016/j.bbmt.2009.11.011
Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nature reviews. Clin Oncol (R Coll Radiol). 2016;13:10–24.
Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2013;121:849–57.
pubmed: 23165479
doi: 10.1182/blood-2012-08-453399
Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88:1019–24.
pubmed: 19855248
pmcid: 4324621
doi: 10.1097/TP.0b013e3181b9d710
Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1392–8.
pubmed: 25985919
pmcid: 4506716
doi: 10.1016/j.bbmt.2015.05.001
Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant. 2012;47:508–15.
pubmed: 21691261
doi: 10.1038/bmt.2011.131
Chang YJ, Zhao XY, Xu LP, Zhang XH, Wang Y, Han W, et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol. 2015;8:84.
pubmed: 26156584
pmcid: 4496923
doi: 10.1186/s13045-015-0182-9
Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010;115:2704–8.
pubmed: 20089963
pmcid: 2852369
doi: 10.1182/blood-2009-09-244525
Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011;118:5957–64.
pubmed: 21967975
pmcid: 3761379
doi: 10.1182/blood-2011-06-362111
Brunstein CG, Noreen H, DeFor TE, Maurer D, Miller JS, Wagner JE. Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011;17:1704–8.
pubmed: 21601639
pmcid: 3168972
doi: 10.1016/j.bbmt.2011.04.013
Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118:6691–7.
pubmed: 21940825
pmcid: 3976219
doi: 10.1182/blood-2011-05-355263
Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010;116:2839–46.
pubmed: 20628152
doi: 10.1182/blood-2009-10-249219
Ruggeri A, Rocha V, Masson E, Labopin M, Cunha R, Absi L, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Societe Francophone d’Histocompatibilite et d’Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis. Haematologica . 2013;98:1154–60.
pubmed: 23242594
pmcid: 3696621
doi: 10.3324/haematol.2012.077685
Takanashi M, Fujiwara K, Tanaka H, Satake M, Nakajima K. The impact of HLA antibodies on engraftment of unrelated cord blood transplants. Transfusion. 2008;48:791–3.
pubmed: 18366463
doi: 10.1111/j.1537-2995.2008.01678.x
Ciurea SO, Cao K, Fernadez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2018;53:521–34.
pubmed: 29335625
doi: 10.1038/s41409-017-0062-8
pmcid: 7232774
Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–51.
pubmed: 11567988
doi: 10.1182/blood.V98.7.2043
Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant. 1995;15:663–8.
pubmed: 7670393
Bastida JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, Sanchez-Guijo F, Lopez-Corral L, et al. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome. Leuk Res. 2015;39:828–34.
pubmed: 26009156
doi: 10.1016/j.leukres.2015.05.003
Gonzalez-Vicent M, Molina B, Deltoro N, Sevilla J, Vicario JL, Castillo A, et al. Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: faster immune reconstitution using younger donors. Leuk Res. 2017;57:60–4.
pubmed: 28292719
doi: 10.1016/j.leukres.2017.03.001
Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2018;93:246–53.
pubmed: 29114918
doi: 10.1002/ajh.24963
Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, et al. Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018;24:1232–6.
pubmed: 28918304
doi: 10.1016/j.bbmt.2017.09.005
Solomon SR, Aubrey MT, Zhang X, Piluso A, Freed BM, Brown S, et al. Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables. Biol Blood Marrow Transplant. 2018;24:789–98.
pubmed: 29355721
doi: 10.1016/j.bbmt.2018.01.013
McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, et al. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv. 2018;2:299–307.
pubmed: 29440002
pmcid: 5812334
doi: 10.1182/bloodadvances.2017014829
Zhang C, Chen XH, Zhang X, Gao L, Gao L, Kong PY, et al. Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings. Transfus Med. 2010;20:169–77.
pubmed: 20136781
pmcid: 2871169
doi: 10.1111/j.1365-3148.2010.00990.x
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Eng J Med. 2014;371:2488–98.
doi: 10.1056/NEJMoa1408617
Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time–a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 1996;17:13–8.
pubmed: 8673048
Stern M, Brand R, de Witte T, Sureda A, Rocha V, Passweg J, et al. Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transplant. 2008;8:2149–57.
pubmed: 18828773
doi: 10.1111/j.1600-6143.2008.02374.x
Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, et al. Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? Biol Blood Marrow Transplant. 2015;21:713–9.
pubmed: 25540936
doi: 10.1016/j.bbmt.2014.12.018
Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C, et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood. 2008;112:2990–5.
pubmed: 18492955
pmcid: 2962448
doi: 10.1182/blood-2008-01-135285
van Rood JJ, Loberiza FR Jr., Zhang MJ, Oudshoorn M, Claas F, Cairo MS, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002;99:1572–7.
pubmed: 11861270
doi: 10.1182/blood.V99.5.1572
van Rood JJ, Zhang L, van Leeuwen A, Claas FH. Neonatal tolerance revisited. Immunol Lett. 1989;21:51–4.
pubmed: 2656515
doi: 10.1016/0165-2478(89)90011-4
Claas F, Gijbels Y, van der Velden-de Munck J, van Rood J. Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life. Science. 1988;241:1815–7.
pubmed: 3051377
doi: 10.1126/science.3051377
Burlingham WJ, Grailer AP, Heisey DM, Claas FH, Norman D, Mohanakumar T, et al. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. N Eng J Med. 1998;339:1657–64.
doi: 10.1056/NEJM199812033392302
Polchi P, Lucarelli G, Galimberti M, Giardini C, Baronciani D, Angelucci E, et al. Haploidentical bone marrow transplantation from mother to child with advanced leukemia. Bone Marrow Transplant. 1995;16:529–35.
pubmed: 8528168
Tamaki S, Ichinohe T, Matsuo K, Hamajima N, Hirabayashi N, Dohy H. Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts. Bone Marrow Transplant. 2001;28:375–80.
pubmed: 11571510
doi: 10.1038/sj.bmt.1703146
Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors. Biol Blood Marrow Transplant. 2018;24:1099–102.
pubmed: 29452245
pmcid: 6439277
doi: 10.1016/j.bbmt.2018.02.005
Zhang YY, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies. Bone Marrow Transplant. 2014;49:496–501.
pubmed: 24510070
doi: 10.1038/bmt.2013.223
Kanda J, Ichinohe T, Matsuo K, Benjamin RJ, Klumpp TR, Rozman P, et al. Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion. 2009;49:624–35.
pubmed: 19170998
doi: 10.1111/j.1537-2995.2008.02043.x
Benjamin RJ, McGurk S, Ralston MS, Churchill WH, Antin JH. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion. 1999;39:179–87.
pubmed: 10037129
doi: 10.1046/j.1537-2995.1999.39299154733.x
Goldman J, Liesveld J, Nichols D, Heal J, Blumberg N. ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation. Leuk Res. 2003;27:489–91.
pubmed: 12648507
doi: 10.1016/S0145-2126(02)00259-X
Stussi G, Muntwyler J, Passweg JR, Seebach L, Schanz U, Gmur J, et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30:87–93.
pubmed: 12132047
doi: 10.1038/sj.bmt.1703621
Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS, et al. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21:746–54.
pubmed: 25572032
pmcid: 4363312
doi: 10.1016/j.bbmt.2014.12.036
Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, et al. Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017;102:1066–74.
pubmed: 28255020
pmcid: 5451338
doi: 10.3324/haematol.2016.160804
Scholl S, Klink A, Mugge LO, Schilling K, Hoffken K, Sayer HG. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. Transfusion. 2005;45:1676–83.
pubmed: 16181220
doi: 10.1111/j.1537-2995.2005.00578.x
Russo A, Oliveira G, Berglund S, Greco R, Gambacorta V, Cieri N, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131:247–62.
pubmed: 28986344
pmcid: 5757695
doi: 10.1182/blood-2017-05-780668
Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21:2145–52.
pubmed: 17673900
doi: 10.1038/sj.leu.2404892
Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–9.
pubmed: 10381530
doi: 10.1182/blood.V94.1.333.413a31_333_339
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–100.
pubmed: 11896281
doi: 10.1126/science.1068440
Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172:644–50.
pubmed: 14688377
doi: 10.4049/jimmunol.172.1.644
Michaelis SU, Mezger M, Bornhauser M, Trenschel R, Stuhler G, Federmann B, et al. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts. Ann Hematol. 2014;93:1579–86.
pubmed: 24771045
doi: 10.1007/s00277-014-2084-2
Oevermann L, Michaelis SU, Mezger M, Lang P, Toporski J, Bertaina A, et al. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood. 2014;124:2744–7.
pubmed: 25115891
pmcid: 4208288
doi: 10.1182/blood-2014-03-565069
Mancusi A, Ruggeri L, Urbani E, Pierini A, Massei MS, Carotti A, et al. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. Blood. 2015;125:3173–82.
pubmed: 25769621
doi: 10.1182/blood-2014-09-599993
Wanquet A, Bramanti S, Harbi S, Furst S, Legrand F, Faucher C, et al. Killer cell immunoglobulin-like receptor-ligand mismatch in donor versus recipient direction provides better graft-versus-tumor effect in patients with hematologic malignancies undergoing allogeneic T cell-replete haploidentical transplantation followed by post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2018;24:549–54.
pubmed: 29247781
doi: 10.1016/j.bbmt.2017.11.042
Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010;16:533–42.
pubmed: 19961944
doi: 10.1016/j.bbmt.2009.11.022
Shimoni A, Labopin M, Lorentino F, Van Lint MT, Koc Y, Gulbas Z, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2019;33:230–9.
pubmed: 29907809
doi: 10.1038/s41375-018-0170-5
Huang XJ, Zhao XY, Liu DH, Liu KY, Xu LP. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia. 2007;21:848–51.
pubmed: 17268518
doi: 10.1038/sj.leu.2404566
Hosokai R, Masuko M, Shibasaki Y, Saitoh A, Furukawa T, Imai C. Donor killer immunoglobulin-like receptor haplotype B/x induces severe acute graft-versus-host disease in the presence of human leukocyte antigen mismatch in T cell-replete hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23:606–11.
pubmed: 28042021
doi: 10.1016/j.bbmt.2016.12.638
Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59:473–81.
pubmed: 24850801
doi: 10.1093/cid/ciu364
Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20:1975–81.
pubmed: 25263628
pmcid: 4343203
doi: 10.1016/j.bbmt.2014.08.013
Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhauser M, Groth C, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Eng J Med. 2014;370:1781–9.
doi: 10.1056/NEJMoa1309533
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Eng J Med. 2017;377:2433–44.
doi: 10.1056/NEJMoa1706640
Matthes-Martin S, Lion T, Aberle SW, Fritsch G, Lawitschka A, Bittner B, et al. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant. 2003;31:803–8.
pubmed: 12732888
doi: 10.1038/sj.bmt.1703927
Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, Thao L, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood. 2009;113:6465–76.
pubmed: 19369230
pmcid: 2710937
doi: 10.1182/blood-2009-02-203307
Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S, et al. The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. Bone Marrow Transplant. 2016;51:1134–6.
pubmed: 26999460
doi: 10.1038/bmt.2016.69
Cesaro S, Crocchiolo R, Tridello G, Knelange N, Van Lint MT, Koc Y, et al. Comparable survival using a CMV-matched or a mismatched donor for CMV + patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplant. 2018;53:422–30.
pubmed: 29330396
doi: 10.1038/s41409-017-0016-1
Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200–6.
pubmed: 12010826
doi: 10.1182/blood.V99.11.4200
Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29:79–91.
pubmed: 2249952
doi: 10.1016/0198-8859(90)90071-V
Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007;110:2235–41.
pubmed: 17554059
doi: 10.1182/blood-2007-02-072405
Raiola AM, Risitano A, Sacchi N, Giannoni L, Signori A, Aquino S, et al. Impact of HLA disparity in haploidentical bone marrow transplantation followed by high-dose cyclophosphamide. Biol Blood Marrow Transplant. 2018;24:119–26.
pubmed: 29024804
doi: 10.1016/j.bbmt.2017.10.002
Lorentino F, Labopin M, Fleischhauer K, Ciceri F, Mueller CR, Ruggeri A, et al. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv. 2017;1:669–80.
pubmed: 29296709
pmcid: 5727822
doi: 10.1182/bloodadvances.2017006429
Huo MR, Pei XY, Li D, Chang YJ, Xu LP, Zhang XH, et al. Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplant. 2018;53:600–8.
pubmed: 29335631
doi: 10.1038/s41409-017-0072-6
Foundation for the Accreditation of Cellular Therapy and Joint Accreditation Committee ISCT EBMT. International standards for hematopoietic cellular therapy product collection, processing and administration. 7th ed. Nebraska:FACT-JACIE, 2018. http://www.factweb.org/forms/store/ProductFormPublic/seventh-edition-fact-jacie-internationalstandards-for-hematopoietic-cellular-therapy-product-collection-processing-and-administration-free-download (viewed Nov 2018).